A Phase 4 interventional study of Fluticasone Furoate/Vilanterol and Vilanterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 45 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-04-10.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2014, is one of 13 in phase 4, and was the 7th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 25 interventional studies. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 80th largest by enrollment of the 236 interventional ones that give a count, is one of 19 that started in 2014, is one of 38 in phase 4, and was the 175th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
1 of the studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks. The primary objective of this study is to evaluate the effect of the inhaled corticosteroid FF on bone mineral density assessed at the total hip by comparing FF/VI treatment with VI treatment in subjects with moderate COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
Drug: Fluticasone Furoate/Vilanterol
Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
Drug: Vilanterol
Drug pages: Fluticasone furoate · Vilanterol
Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Percentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip
BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Male Participants)
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Female Participants)
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Male Participants)
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Female Participants)
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4)
BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
The study was conducted on participants with chronic obstructive pulmonary disease (COPD) in five countries to assess the long-term safety effects of Fluticasone Furoate (FF) component of the FF/Vilanterol (VI) inhalation powder.
| Milestone | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Started | 142 | 141 |
| Completed | 87 | 83 |
| Not completed | 55 | 58 |
| Withdrew: Adverse event | 23 | 20 |
| Withdrew: Withdrawal by subject | 13 | 17 |
| Withdrew: Physician decision | 3 | 6 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lack of efficacy | 11 | 11 |
BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percentage change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Overall % change per year, n = 132, 130 | 0.18 (-0.18 to 0.55) | -0.27 (-0.63 to 0.09) |
| % change by Week 26, n= 130, 130 | 0.37 (-0.07 to 0.82) | 0.31 (-0.13 to 0.76) |
| % change by Week 52, n = 104, 121 | 0.35 (-0.21 to 0.91) | -0.43 (-0.96 to 0.10) |
| % change by Week 78, n = 97, 102 | 0.22 (-0.41 to 0.85) | -0.68 (-1.29 to -0.07) |
| % change by Week 104, n = 94, 96 | -0.16 (-0.84 to 0.52) | -1.02 (-1.68 to -0.36) |
| % change by Week 130, n = 88, 84 | 0.00 (-0.73 to 0.75) | -1.02 (-1.75 to -0.29) |
| % change by Week 156, n = 76, 75 | -0.16 (-1.02 to 0.71) | -1.29 (-2.13 to -0.45) |
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percent change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Overall Week % change per year, n = 67, 63 | 0.27 (-0.23 to 0.77) | -0.20 (-0.70 to 0.31) |
| % change by Week 26, n = 66, 63 | 0.45 (-0.06 to 0.97) | 0.44 (-0.09 to 0.97) |
| % change by Week 52, n = 52, 56 | 0.48 (-0.31 to 1.27) | -0.43 (-1.19 to 0.33) |
| % change by Week 78, n = 51, 46 | 0.06 (-0.81 to 0.95) | -0.68 (-1.56 to 0.21) |
| % change by Week 104, n = 50, 43 | 0.07 (-0.86 to 1.00) | -0.68 (-1.62 to 0.27) |
| % change by Week 130, n = 44, 39 | 0.37 (-0.75 to 1.50) | -0.89 (-2.02 to 0.26) |
| % change by Week 156, n = 40, 35 | 0.05 (-1.26 to 1.37) | -1.39 (-2.71 to -0.05) |
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percent change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| OverallWeek % change per year, n = 65, 67 | 0.09 (-0.46 to 0.64) | -0.31 (-0.84 to 0.22) |
| % change by Week 26, n = 64, 67 | 0.28 (-0.45 to 1.02) | 0.20 (-0.51 to 0.92) |
| % change by Week 52, n = 52, 65 | 0.13 (-0.67 to 0.94) | -0.42 (-1.16 to 0.33) |
| % change by Week 78, n = 46, 56 | 0.37 (-0.54 to 1.28) | -0.63 (-1.48 to 0.23) |
| % change by Week 104, n = 44, 53 | -0.40 (-1.40 to 0.61) | -1.26 (-2.19 to -0.32) |
| % change by Week 130, n = 44, 45 | -0.18 (-1.12 to 0.77) | -0.99 (-1.90 to -0.08) |
| % change by Week 156, n = 36, 40 | -0.42 (-1.56 to 0.73) | -1.19 (-2.27 to -0.11) |
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percent change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Overall, male % change per year, n = 69, 64 | 1.41 (0.79 to 2.04) | 0.38 (-0.26 to 1.02) |
| % change by Week 26, n = 67, 64 | 1.03 (0.26 to 1.80) | 0.42 (-0.36 to 1.21) |
| % change by Week 52, n = 53, 56 | 1.91 (0.89 to 2.94) | 0.11 (-0.88 to 1.11) |
| % change by Week 78, n = 52, 45 | 2.09 (0.84 to 3.35) | 0.64 (-0.67 to 1.97) |
| % change by Week 104, n = 52, 43 | 2.72 (1.48 to 3.98) | 0.42 (-0.88 to 1.75) |
| % change by Week 130, n = 47, 38 | 1.95 (0.76 to 3.16) | 0.47 (-0.82 to 1.78) |
| % change by Week 156, n = 43, 35 | 2.96 (1.68 to 4.25) | 1.49 (0.13 to 2.86) |
BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percent change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Overall Week % change per year, n = 66, 68 | 0.17 (-0.42 to 0.77) | 0.12 (-0.45 to 0.70) |
| % change by Week 26, n = 66, 68 | 0.10 (-0.67 to 0.88) | -0.19 (-0.95 to 0.58) |
| % change by Week 52, n = 51, 66 | -0.48 (-1.44 to 0.48) | 0.57 (-0.31 to 1.46) |
| % change by Week 78, n = 46, 57 | 0.33 (-0.60 to 1.26) | 0.25 (-0.61 to 1.11) |
| % change by Week 104, n = 43, 54 | 0.65 (-0.50 to 1.80) | 0.64 (-0.41 to 1.70) |
| % change by Week 130, n = 44, 49 | 1.33 (0.01 to 2.67) | 0.10 (-1.12 to 1.33) |
| % change by Week 156, n = 36, 42 | 0.80 (-0.74 to 2.36) | 0.10 (-1.32 to 1.53) |
BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.
| Percentage Change | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| Overall week % change per year, n=135, 132 | 0.79 (0.36 to 1.22) | 0.28 (-0.15 to 0.71) |
| % change by Week 26, n = 133, 132 | 0.55 (0.01 to 1.10) | 0.13 (-0.41 to 0.68) |
| % change by Week 52, n = 104, 122 | 0.71 (0.01 to 1.42) | 0.40 (-0.26 to 1.07) |
| % change by Week 78, n= 98, 102 | 1.20 (0.43 to 1.99) | 0.45 (-0.31 to 1.21) |
| % change by Week 104, n = 95, 97 | 1.66 (0.82 to 2.51) | 0.61 (-0.22 to 1.44) |
| % change by Week 130, n = 91, 87 | 1.70 (0.80 to 2.61) | 0.30 (-0.60 to 1.20) |
| % change by Week 156, n = 79, 77 | 1.84 (0.86 to 2.84) | 0.83 (-0.14 to 1.81) |
Collected over Serious adverse events and non-serious adverse events were collected from randomization of the study until 159 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Administered VI | 6/142 (4.2%) | 42/142 (29.6%) | 102/142 (71.8%) |
| Participants Administered FF/VI | 4/141 (2.8%) | 41/141 (29.1%) | 116/141 (82.3%) |
| Event | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| PneumoniaInfections and infestations | 4/142 | 11/141 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 10/142 | 6/141 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/142 | 3/141 |
| SepsisInfections and infestations | 0/142 | 2/141 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/142 | 2/141 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/142 | 1/141 |
| Atrial fibrillationCardiac disorders | 2/142 | 0/141 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/142 | 1/141 |
| Chronic respiratory failureRespiratory, thoracic and mediastinal disorders | 0/142 | 1/141 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/142 | 1/141 |
| Event | Participants Administered VI | Participants Administered FF/VI |
|---|---|---|
| NasopharyngitisInfections and infestations | 31/142 | 40/141 |
| HeadacheNervous system disorders | 16/142 | 26/141 |
| InfluenzaInfections and infestations | 5/142 | 20/141 |
| Back painMusculoskeletal and connective tissue disorders | 13/142 | 20/141 |
| BronchitisInfections and infestations | 16/142 | 11/141 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/142 | 13/141 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/142 | 13/141 |
| SinusitisInfections and infestations | 3/142 | 13/141 |
| Upper respiratory tract infectionInfections and infestations | 13/142 | 12/141 |
| Urinary tract infectionInfections and infestations | 12/142 | 12/141 |
| Age, Continuous(Years) | Participants Administered VI | Participants Administered FF/VI | Total |
|---|---|---|---|
| Mean | 66.0 ± 8.19 | 64.4 ± 9.04 | 65.2 ± 8.65 |
| Sex: Female, Male(Participants) | Participants Administered VI | Participants Administered FF/VI | Total |
|---|---|---|---|
| Female | 70 | 71 | 141 |
| Male | 72 | 70 | 142 |
| Race/Ethnicity, Customized(Count of participants) | Participants Administered VI | Participants Administered FF/VI | Total |
|---|---|---|---|
| Central/South Asian Heritage | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 2 |
| White | 141 | 139 | 280 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2014 to primary completion in Mar 2018, 49 months.
Results were first posted in Apr 2019, 1 year after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 49 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol
Pulmonary Disease, Chronic Obstructive →